Cargando…
ACEi reduces hypertension-induced hyperinflammation in COVID-19
Antihypertensive therapy, particularly with the use of an angiotensin-converting enzyme inhibitor, improves outcomes in patients with hypertension and SARS-CoV-2 infection, who are susceptible to hyperinflammation and severe outcomes with COVID-19.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812557/ https://www.ncbi.nlm.nih.gov/pubmed/33462417 http://dx.doi.org/10.1038/s41569-021-00512-9 |